BRCA2 and neoplasm: Although BRCA2 mutations, both somatic and germline, have been recently described in SBAs, direct evidence of BRCA2 inactivation in SBA tumor tissue of patients with BRCA2‐related hereditary cancer syndrome is still very limited.